Medical Doctor Program year 2025 Reported 2020–2025 Source: CMS Open Payments, 2026 publication

Theresa Simon

Internal Medicine Point Pleasant, WV Medical Doctor

NPI 1356423016 CMS profile 151592

2520 Valley Drive, Point Pleasant, WV 25550

Open in the dashboard

General payments

$2,310

129 records reported · program years 2020–2025

Research payments

$0

Paid to them · None reported · program years 2020–2025

Ownership & investment interest

$0

None reported

Through program year 2025, Theresa Simon of Point Pleasant, WV is reported in the CMS Open Payments database as having received $2,310 across 129 general payments and $0 in research payments paid to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them.

General payments for this record sit in the 81st percentile of Internal Medicine profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

6 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $326 17
2024 General $348 21
2023 General $595 34
2022 General $825 45
2021 General $166 9
2020 General $50 3

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Theresa Simon
  • Internal Medicine median
  • Middle half of Internal Medicine
  • National median

In program year 2025, general payments to Theresa Simon were reported at $326. Among 52,115 Internal Medicine profiles paid that year, the median was $156 and the middle half received between $47 and $551.

Show as a table
Year Theresa Simon Internal Medicine median Middle half National median
2019 $0 $159 $48–$570 $163
2020 $50 $119 $33–$402 $114
2021 $166 $135 $37–$521 $132
2022 $825 $141 $42–$496 $149
2023 $595 $149 $45–$519 $160
2024 $348 $154 $47–$537 $164
2025 $326 $156 $47–$551 $169

Breakdown

Who paid General payments · program years 2020–2025
  1. AbbVie, Inc. $1,246 66 payments
  2. GlaxoSmithKline, LLC. $213 13 payments
  3. Lilly USA, LLC $159 10 payments
  4. Astellas Pharma US Inc $119 6 payments
  5. Pfizer Inc. $90 6 payments
  6. Novartis Pharmaceuticals Corporation $71 5 payments
  7. Janssen Pharmaceuticals, Inc $65 3 payments
  8. Novo Nordisk Inc $60 4 payments
  9. Merck Sharp & Dohme Corporation $55 3 payments
  10. E.R. Squibb & Sons, L.L.C. $43 3 payments
  11. Other $189 10 payments

Every payment, record by record

What the payments were for General payments · program years 2020–2025
  1. Food and Beverage $2,310 129 payments
Products named General payments · program years 2020–2025
  1. UBRELVY $865 44 payments
  2. QULIPTA $818 46 payments
  3. TRELEGY ELLIPTA $213 13 payments
  4. MOUNJARO $75 5 payments
  5. ENTRESTO $71 5 payments
  6. XARELTO $65 3 payments
  7. Veozah $65 3 payments
  8. LEQVIO $58 4 payments
  9. TRULICITY $58 4 payments
  10. VRAYLAR $55 3 payments
  11. Other $851 52 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Prescribing to Medicare patients

Part D · data year 2024 · 126 drugs

Part D claims

8,533

Median for Internal Medicine: 777

Drug cost

$788,394

Median for Internal Medicine: $73,373

Branded share of claims

21.4%

Median for Internal Medicine: 19.3%

Drugs this doctor was counted under in Medicare Part D 2024, by drug cost
Drug Type Relative to their largest Claims Drug cost
Jardiance Empagliflozin Brand 110 $134,873
Eliquis Apixaban Brand 107 $123,335
Ozempic Semaglutide Brand 115 $115,350
Mounjaro Tirzepatide Brand 71 $93,768
Trelegy Ellipta Fluticasone/Umeclidin/Vilanter Brand 75 $72,706
Farxiga Dapagliflozin Propanediol Brand 25 $31,013
Januvia Sitagliptin Phosphate Brand 19 $29,787
Lantus Solostar Insulin Glargine,hum.Rec.Anlog Brand 68 $14,805
Xarelto Rivaroxaban Brand 12 $14,049
Toujeo Solostar Insulin Glargine,hum.Rec.Anlog Brand 12 $12,104

The 10 drugs with the highest cost, of 126 counted.

Drug cost is what was paid for the drugs at the pharmacy — by Medicare, the patient and others — and is not money to the prescriber. Medicare Part D only: drugs dispensed to Medicare beneficiaries. A drug with fewer than 11 claims for this prescriber is not published, so a missing drug does not mean zero. The medians are for the 104,182 Part D prescribers listed as Internal Medicine; they describe a distribution and say nothing about conduct.

Payments and prescribing

First 5 of 6 products · payments 2024

Two separate records. The payments come from Open Payments and the claims from Medicare. They are set side by side because they name the same product; they do not show that a payment affected a prescription.

Products this doctor was paid in connection with in 2024, beside Medicare claims for the same product
Product Paid by Related payments Part D claims Part B services
UBRELVY
  • AbbVie, Inc. $140
$140 — —
QULIPTA
  • AbbVie, Inc. $133
$133 — —
ZEPBOUND
  • Lilly USA, LLC $16
$16 — —
JARDIANCE
  • Lilly USA, LLC $16
$16 110 —
RYBELSUS
  • Novo Nordisk Inc $7
$7 — —

A dash means Medicare published no figure for this doctor and product — fewer than 11 claims, or the product is not covered under that part — which is not the same as none. Payments are general payments only; one that names several products is split evenly between them, so an amount is payments related to the product, not money paid for it.

See all 6 in the dashboard with a free account

Records

129 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Internal Medicine in West Virginia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record